Barbara Kahn is Director at DEXCOM INC (DXCM). They have made 14 open-market trades across 1 company since 2013, most recently 2024-05-18.
CIK 0001520391
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DXCM | 22,575 | $2.0M |
Shares reported on the most recent Form 4, priced at the 2024-05-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DXCM | SELL | 2022-02-10 | 2022-02-14 | $441.06 | $3.0M | -0.9% | +5.3% | -21.8% |
| DXCM | SELL | 2020-06-10 | 2020-06-12 | $380.71 | $2.7M | +8.6% | +11.4% | +7.4% |
| DXCM | SELL | 2019-12-12 | 2019-12-16 | $204.48 | $2.8M | +2.3% | +9.9% | -5.1% |
| DXCM | SELL | 2019-01-14 | 2019-01-16 | $142.30 | $3.0M | -4.9% | +0.8% | -20.0% |
| DXCM | SELL | 2017-11-20 | 2017-11-20 | $54.58 | $164K | +5.4% | +3.0% | +3.7% |
| DXCM | SELL | 2017-03-14 | 2017-03-16 | $77.36 | $232K | +8.7% | -2.6% | -3.4% |
| DXCM | SELL | 2016-08-08 | 2016-08-10 | $90.52 | $543K | -0.4% | +2.3% | -31.1% |
| DXCM | SELL | 2016-05-12 | 2016-05-12 | $60.72 | $182K | +6.7% | +18.4% | +48.2% |
| DXCM | SELL | 2016-03-07 | 2016-03-08 | $67.04 | $670K | -8.3% | +3.4% | +3.6% |
| DXCM | SELL | 2015-03-05 | 2015-03-09 | $60.29 | $181K | -11.2% | -2.2% | -2.2% |
| DXCM | SELL | 2014-08-28 | 2014-09-02 | $44.52 | $178K | -11.2% | -2.2% | -2.2% |
| DXCM | SELL | 2014-08-21 | 2014-08-21 | $43.42 | $96K | -11.2% | -2.2% | -2.2% |
| DXCM | SELL | 2014-05-08 | 2016-09-14 | $55.23 | $690K | +1.8% | -10.8% | -29.0% |
| DXCM | SELL | 2013-11-22 | 2013-12-06 | $32.63 | $49K | -11.2% | -2.2% | -2.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.